secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2026-06-02T20:05:28+00:00
Accession:  0001193125-26-253478
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies annual meeting elects directors, ratifies auditor, approves say-on-pay
--------------------------------------------------------------------------------

- Shareholders elected Sean P. Nolan (169.1M for) and Laura Sepp-Lorenzino (150.1M for) as directors until 2029.
- Deloitte & Touche ratified as independent auditor for FY2026 with 243.8M votes for.
- Non-binding advisory vote on named executive officer compensation approved: 168.1M for vs 36.4M against.
- Advisory vote on frequency of say-on-pay: annual basis chosen with 203.8M votes for one year.
- Approximately 84.86% of outstanding shares were represented at the meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/0001193125-26-253478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/d159199d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-253478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer